Physician profile
David Blady
NPI 1053386144
$3,300.81
in general payments reported to CMS, 2019-2025
11 companies · $384 in 2025
The $384 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $228 · 2021: $1,100 · 2022: $234 · 2023: $857 · 2024: $164 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551 · Consulting Fee: $505 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.50 |
| Consulting Fee | $505.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $950.00 | 2021 | |
| Abbvie INC. | $666.11 | 2023-2024 | Ubrelvy, Qulipta |
| Biogen, INC. | $600.00 | 2019-2025 | Tysabri |
| E.R. Squibb & Sons, L.L.C. | $304.31 | 2022-2025 | Zeposia |
| Amneal Pharmaceuticals LLC | $205.00 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $123.29 | 2019 | |
| Lilly USA, LLC | $120.59 | 2020 | |
| Argenx US, INC. | $117.89 | 2025 | Vyvgart |
| Genentech USA, INC. | $107.00 | 2020 | |
| Acorda Therapeutics, INC | $60.19 | 2019 | |
| Celgene Corporation | $46.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Blady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.